MX2010004698A - Composicion. - Google Patents

Composicion.

Info

Publication number
MX2010004698A
MX2010004698A MX2010004698A MX2010004698A MX2010004698A MX 2010004698 A MX2010004698 A MX 2010004698A MX 2010004698 A MX2010004698 A MX 2010004698A MX 2010004698 A MX2010004698 A MX 2010004698A MX 2010004698 A MX2010004698 A MX 2010004698A
Authority
MX
Mexico
Prior art keywords
mbp
composition
relates
treat
disease
Prior art date
Application number
MX2010004698A
Other languages
English (en)
Inventor
David Wraith
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of MX2010004698A publication Critical patent/MX2010004698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)

Abstract

La presente invención se refiere a una composición que comprende los siguientes péptidos de proteína básica de mielina: MBP 30-44; MBP 83-99; MBP 131-145; y MBP 140-154; la composición puede usarse para tratar una enfermedad, en particular esclerosis múltiple y/o neuritis óptica, y la invención se refiere también a dichos usos y métodos.
MX2010004698A 2007-10-31 2008-10-30 Composicion. MX2010004698A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (1)

Publication Number Publication Date
MX2010004698A true MX2010004698A (es) 2010-05-13

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004698A MX2010004698A (es) 2007-10-31 2008-10-30 Composicion.

Country Status (24)

Country Link
US (3) US8623827B2 (es)
EP (1) EP2211892B1 (es)
JP (1) JP5361895B2 (es)
KR (1) KR101570383B1 (es)
CN (1) CN101848725B (es)
AT (1) ATE518546T1 (es)
AU (1) AU2008320657B2 (es)
BR (1) BRPI0818302B1 (es)
CA (1) CA2703170C (es)
CY (1) CY1112620T1 (es)
DK (1) DK2211892T3 (es)
EA (1) EA017999B1 (es)
EC (1) ECSP10010211A (es)
HK (1) HK1142803A1 (es)
HR (1) HRP20110724T1 (es)
IL (1) IL204662A (es)
MX (1) MX2010004698A (es)
MY (1) MY158800A (es)
NZ (1) NZ583924A (es)
PL (1) PL2211892T3 (es)
PT (1) PT2211892E (es)
SI (1) SI2211892T1 (es)
WO (1) WO2009056833A2 (es)
ZA (1) ZA201001748B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030191063A1 (en) 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition
KR20120103591A (ko) 2009-10-12 2012-09-19 라이프바이오 라보라토리즈 엘엘씨 다발성 경화증 치료용 조성물
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
CA3049177A1 (en) * 2017-01-04 2018-07-12 Apitope Technology (Bristol) Limited Therapeutic method using tolerogenic peptides
CN111225681A (zh) * 2017-08-14 2020-06-02 艾匹托普技术(布里斯托尔)有限公司 方法
CA3215545A1 (en) 2021-04-16 2022-10-20 John PUISIS Method of tracking maintenance of immunological tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20030191063A1 (en) * 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition

Also Published As

Publication number Publication date
EA017999B1 (ru) 2013-04-30
IL204662A0 (en) 2010-11-30
MY158800A (en) 2016-11-15
WO2009056833A3 (en) 2009-11-26
CN101848725A (zh) 2010-09-29
CA2703170A1 (en) 2009-05-07
AU2008320657A1 (en) 2009-05-07
US20160263188A1 (en) 2016-09-15
KR20100036391A (ko) 2010-04-07
BRPI0818302B1 (pt) 2022-04-12
JP5361895B2 (ja) 2013-12-04
AU2008320657B2 (en) 2013-09-05
US9381234B2 (en) 2016-07-05
EP2211892A2 (en) 2010-08-04
EP2211892B1 (en) 2011-08-03
CN101848725B (zh) 2013-05-22
ZA201001748B (en) 2011-06-29
WO2009056833A2 (en) 2009-05-07
CA2703170C (en) 2016-10-11
JP2011500776A (ja) 2011-01-06
IL204662A (en) 2013-07-31
US9775880B2 (en) 2017-10-03
HK1142803A1 (en) 2010-12-17
US20140161832A1 (en) 2014-06-12
BRPI0818302A2 (es) 2018-08-21
US20100286054A1 (en) 2010-11-11
PL2211892T3 (pl) 2012-01-31
SI2211892T1 (sl) 2011-12-30
CY1112620T1 (el) 2016-02-10
DK2211892T3 (da) 2011-10-31
PT2211892E (pt) 2011-10-18
ATE518546T1 (de) 2011-08-15
ECSP10010211A (es) 2010-08-31
US8623827B2 (en) 2014-01-07
EA201070541A1 (ru) 2010-12-30
HRP20110724T1 (hr) 2011-12-31
KR101570383B1 (ko) 2015-11-19
NZ583924A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
IL204662A0 (en) Composition
WO2017191274A3 (en) Rna encoding a therapeutic protein
PH12015502433A1 (en) Fgf21 mutants and uses thereof
EA201001322A1 (ru) Вакцины против хламидиоза
TN2014000134A1 (en) Therapeutic peptides
EA201001883A1 (ru) Мутанты fgf21 и их применение
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
TN2011000161A1 (en) Fgf21 mutants and uses thereof
MX2018000590A (es) Moleculas de anticuerpo que se unen a agrupacion de diferenciacion 79 (cd79).
EA201590910A1 (ru) Белки на основе структурного домена фибронектина, связывающие pcsk9
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
IN2012DN02589A (es)
MX2015011199A (es) Agentes terapéuticos de csf1.
WO2010014830A3 (en) Peptide therapeutics that bind vegf and methods of use thereof
WO2009138494A3 (en) Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2010046461A3 (en) Treatment of intracellular bacterial infections
WO2007044989A3 (en) Modulators of nod1 signaling
GB0818080D0 (en) Immunogenic peptides
UA107458C2 (uk) Мутанти fgf21 та їх застосування
UA102395C2 (en) Fgf21 mutants and use thereof
EA200970792A1 (ru) Аморфный твёрдый раствор, содержащий производное пиразол-3-карбоксамида в аморфной форме и стабилизирующие эксципиенты

Legal Events

Date Code Title Description
FG Grant or registration